Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou 510623, China.
Department of Otolaryngology, Liuzhou hospital of Guangzhou Women and Children's Medical Center, Guangxi 545001, China.
Mediators Inflamm. 2023 Apr 14;2023:1572891. doi: 10.1155/2023/1572891. eCollection 2023.
BACKGROUND: Interleukin-37b is a fundamental inhibitor of innate and acquired immunity. Type 2 innate lymphoid cells (ILC2s) can secret type 2 cytokines and regulate allergic rhinitis (AR). However, the role of IL-37b in ILC2s in children with AR was not clear. METHODS: We recruited 15 AR children and controls. The serum IL-37b levels and its relation with the frequency and functional phenotype of ILC2s. The regulation of IL-37b on ILC2s proliferation and function was confirmed using flow cytometry and enzyme-linked immunosorbent assay (ELISA). The mRNA expression of IL-1R8, IL-18R, and ICOSL was examined using RCR. The change of IL-37b protein level in serum during subcutaneous allergen immunotherapy (SCIT) was determined by ELISA. RESULTS: We have demonstrated that both of the frequencies of blood ILC2s, IL-5+ILC2s, and IL-13+ILC2s in AR children were elevated compared with controls. The serum protein level of IL-37b was downregulated in AR, and it was negatively related to the frequency of ILC2s, IL-5+ILC2s, and IL-13+ILC2s. IL-37b increased the mRNA levels of IL-1R8, IL-18R, and ICOSL expressed by ILC2s. IL-37b suppressed the proliferation of ILC2s and the secretion of IL-5 and IL-13 from ILC2s. Finally, we found that IL-37b was increased in AR children after 3 years' SLIT, especially in the good response group. CONCLUSION: Our findings highlight the role of IL-37b in the suppression of ILC2s and establish a new therapeutic target in AR.
背景：白细胞介素-37b 是先天和获得性免疫的基本抑制剂。2 型固有淋巴细胞（ILC2s）可以分泌 2 型细胞因子并调节过敏性鼻炎（AR）。然而，IL-37b 在 AR 患儿 ILC2s 中的作用尚不清楚。
方法：我们招募了 15 名 AR 患儿和对照组。检测血清 IL-37b 水平及其与 ILC2s 频率和功能表型的关系。采用流式细胞术和酶联免疫吸附试验（ELISA）证实了 IL-37b 对 ILC2s 增殖和功能的调节。采用 RCR 检测 IL-1R8、IL-18R 和 ICOSL 的 mRNA 表达。采用 ELISA 检测血清中 IL-37b 蛋白水平在皮下变应原免疫治疗（SCIT）过程中的变化。
结果：我们发现 AR 患儿血液 ILC2s、IL-5+ILC2s 和 IL-13+ILC2s 的频率均高于对照组。AR 患者血清 IL-37b 蛋白水平下调，与 ILC2s、IL-5+ILC2s 和 IL-13+ILC2s 的频率呈负相关。IL-37b 增加了 ILC2s 表达的 IL-1R8、IL-18R 和 ICOSL 的 mRNA 水平。IL-37b 抑制 ILC2s 的增殖和 ILC2s 分泌 IL-5 和 IL-13。最后，我们发现经过 3 年 SLIT 后，AR 患儿的 IL-37b 增加，尤其是在反应良好的组中。
结论：我们的研究结果强调了 IL-37b 在抑制 ILC2s 中的作用，并为 AR 建立了一个新的治疗靶点。
Mediators Inflamm. 2023
Chin Med J (Engl). 2016-12-5
Mediators Inflamm. 2014
Iran J Immunol. 2021-9
Biomedicines. 2025-5-21
J Allergy Clin Immunol. 2022-3
Front Immunol. 2021
Allergy. 2021-11
Front Immunol. 2021
Pediatr Allergy Immunol. 2021-1
Biomed Pharmacother. 2019-12-30
Cytokine Growth Factor Rev. 2019-10-18
Biomed Res Int. 2018-4-1
Int Forum Allergy Rhinol. 2018-2
Zotero 插件
